CAR-T therapy study for advanced blood and solid cancers
Part of Cancer clinical trials.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced blood cancer (like multiple myeloma or lymphoma) or solid tumor (like small cell lung cancer) that has come back or not responded to treatment.
- Your cancer cells have a specific target protein (like BCMA, GPRC5D, or DLL3) that the therapy is designed to attack.
- You are generally able to care for yourself (ECOG score 0-2 for blood cancers or 0-1 for solid tumors) and expected to live at least 3 more months.
- Your major organs (like heart, kidneys, liver) are working well enough.
- If you can become pregnant, you agree to use effective birth control during the study and for 1 year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR-T cells, which are engineered to attack cancer cells that have certain markers (CD19 or BCMA). It is for people with blood cancers like multiple myeloma or certain lymphomas that have not responded to multiple prior treatments. The goal is to see if this treatment can help when other options have failed.
This trial is testing a new type of cell therapy that uses your own immune cells (called CAR-T cells) to fight your cancer. The cells are modified to attack two specific targets on your cancer cells (BCMA and GPRC5D) to potentially improve treatment response.
This trial is testing a new CAR-T cell therapy given as an injection for people with advanced or metastatic solid tumors that have stopped responding to standard treatments. CAR-T therapy uses your own immune cells to target and attack cancer cells. It may be an option if you have tried other treatments and they are no longer working.
This trial tests a new type of immune cell therapy (CAR-T) that targets specific proteins (CD73 and AXL) on tumor cells. It is for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this therapy can shrink tumors or slow their growth.
This trial tests a new immune cell therapy (CAR-T) that targets two markers on high-risk plasma cell cancers. It aims to see if this treatment is safe and helpful for people with aggressive or resistant forms of this disease.
This trial is testing a new immunotherapy treatment using CAR-T cells for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The treatment aims to target and destroy myeloma cells that have BCMA and GPRC5D proteins on their surface.
Hear when a new Advanced Malignant Tumours trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.